On May 1, the U.S. Food and Drug Administration approved CAR-T cell therapy developed by Penn Medicine for use in the most common form of non-Hodgkin’s lymphoma. This breakthrough means that more patients will be able to receive the potentially life-saving treatment.

Click here to read more.
 



Staff at the Ann B. Barshinger Cancer Institute gathered May 2 to celebrate a second FDA approval of the Penn Medicine-developed CAR-T cell therapy, this time for adult patients with non-Hodgkin’s lymphoma. 


 

Share This Page: